Key Takeaways
|
If you are considering a weight loss injection, you will quickly come across two names: Mounjaro and Ozempic. Friends, social media and online sellers often present one as better than the other.
The truth is more careful. Both are effective, both have real risks and the right choice depends on the person. This guide compares the weight loss injections Mounjaro (tirzepatide) and Ozempic (semaglutide).
Not sure which approach suits your weight or blood sugar?
Tirzepatide vs Semaglutide
Tirzepatide and semaglutide copy hormones that your gut makes after a meal. These hormones lower appetite, slow stomach emptying and help the pancreas release insulin when blood sugar is high.
| Semaglutide (Ozempic, Wegovy) copies GLP-1 only. Tirzepatide (Mounjaro) copies GLP-1 and a second hormone, GIP. The extra action may add to the effect on appetite and blood sugar (Coskun et al., 2018). |
In simple terms, tirzepatide is sometimes called a “dual” medicine and semaglutide a “single” one.
Mounjaro vs Ozempic – The Key Differences
Mounjaro and Ozempic are once-weekly injectable medicines that help manage blood sugar levels and can also support weight loss. However, they contain different active ingredients and work through different hormonal pathways. Mounjaro (tirzepatide) acts on two hormone receptors, GIP and GLP-1, while Ozempic (semaglutide) acts on GLP-1 receptors alone.
| Mounjaro | Ozempic | |
| Medicine | Tirzepatide | Semaglutide |
| Hormones copied | GIP and GLP-1 | GLP-1 |
| Maker | Eli Lilly | Novo Nordisk |
| How it is given | Once-weekly injection under the skin, vial or KwikPen | Once-weekly injection under the skin, pen |
| Usual starting dose | 2.5 mg weekly for 4 weeks, then raised in steps of 2.5 mg at least 4 weeks apart, up to 15 mg | 0.25 mg weekly for 4 weeks, then 0.5 mg, with steps up to 1 mg and 2 mg if needed |
| Approved in India for | Type 2 diabetes and weight management | Type 2 diabetes. The same medicine at a higher dose, Wegovy, is for weight management |
| Average weight loss in obesity trials | About 15 to 21 per cent, depending on dose | About 15 per cent with the 2.4 mg Wegovy dose |
| Most common side effects | Nausea, diarrhoea, vomiting, constipation, reduced appetite | Nausea, vomiting, diarrhoea, constipation, stomach pain |
| Heart outcome evidence | Newer, with less long-term data | Trials showing fewer heart attacks and strokes in people with heart disease or diabetes |
| Indian availability | Sold in India as Mounjaro | Brand and, since March 2026, several Indian generic semaglutide injections |
The dose steps above are examples from the product information, and your doctor will set your own plan. The slow step-up is deliberate. It helps your body get used to the medicine and reduces stomach side effects.
“Weight reduction by controlling hunger can be really effective for managing weight, but it’s important to remember that it’s a gradual process that depends on the medication. To get the most out of GLP-1 therapy in the long run, it’s helpful to pair it with mindful eating habits like listening to your body’s cues and enjoying your meals slowly. This combination can lead to lasting, positive results!”
– Dr. Priyadarshini Bhalekar, Zonal Medical Head, Madhavbaug
Which Works Better for Weight Loss?
If your main goal is weight loss, Mounjaro may offer greater average results than Ozempic. In the SURMOUNT-5 trial, 751 adults with obesity but without diabetes received either tirzepatide or semaglutide at their highest tolerated dose. After 72 weeks, people taking tirzepatide lost an average of 20.2% of their body weight, compared with 13.7% with semaglutide (Aronne et al., 2025). Waist circumference also decreased more with tirzepatide.
However, these figures are averages, not a promise of how much weight you will lose. Your results may differ depending on your health, treatment dose and response to the medicine.
Which Works Better for Type 2 Diabetes?
Both Mounjaro and Ozempic help lower blood sugar in people with type 2 diabetes, but clinical evidence suggests that tirzepatide may offer a greater reduction in both blood sugar and body weight.
In the SURPASS-2 trial, adults with type 2 diabetes taking metformin received tirzepatide or semaglutide 1 mg for 40 weeks. HbA1c levels fell by around 2.0–2.3 percentage points with tirzepatide, compared with 1.9 percentage points with semaglutide. Average weight loss was also greater with tirzepatide, at around 8–11 kg compared with 6 kg (Frias et al., 2021).
Both medicines were effective, but the better option for you depends on your blood sugar levels, weight management goals, existing medicines and overall health. Your doctor can help you choose the treatment that best suits your needs.
| Clinical Insight “In my 19 years of clinical experience, I have seen that diabetes management is different for every patient. The aim is to control blood sugar while achieving a healthy weight, with treatment tailored to the patient’s condition and response to medication.” Dr. Gurudatta Amin, BAMS, MD, PGDEMS, 19+ Years of Clinical Experience, CMO, Madhavbaug |
Side Effects
The side-effect pattern is very similar, because the medicines work in a similar way. Nausea, vomiting, diarrhoea and constipation are the most common, especially during dose increases. In SURMOUNT-5, stopping treatment because of stomach side effects was less common with tirzepatide (2.7 per cent) than with semaglutide (5.6 per cent) (Aronne et al., 2025). Both carry warnings about pancreatitis, gallbladder disease and a possible risk of thyroid C-cell tumours seen in animal studies.
One difference is worth knowing. Tirzepatide can reduce how well birth control pills work, particularly in the weeks after starting or raising the dose, so women who use them should ask their doctor about extra protection.
What About Long-Term and Heart Evidence?
Semaglutide has been used for longer and has more long-term outcome data. In adults with diabetes, semaglutide lowered the risk of major cardiovascular events (Marso et al., 2016), and in adults with obesity and heart disease but no diabetes, it did the same (Lincoff et al., 2023). Tirzepatide is newer, and its long-term evidence is still growing. Your doctor will consider your heart and kidney health when advising which medicine to use.
How Do You Choose Between Them?
The decision usually depends on many factors, like your main goal, any existing condition or medicines that you are consuming, pregnancy and much more. Following the detailed description for the questions.
| Question | Why it matters |
| Is the main goal weight loss, blood sugar control or both? | Both medicines help both goals, but the size of effect differs |
| Do you have heart disease, kidney disease or other conditions? | This can favour one medicine or need extra care |
| How did you tolerate earlier medicines? | Stomach tolerance varies widely |
| Which products and doses can you get safely, and at what cost? | Prices differ, and semaglutide generics have arrived in India since March 2026 |
| Are you planning pregnancy, or do you use birth control pills? | Both need planning, and tirzepatide has the pill interaction |
If you take other diabetes tablets or insulin, your doctor may need to change those doses to avoid low blood sugar. Never use two GLP-1 injections together, and do not switch from one to the other on your own, because the doses do not match one for one.
| What Does Not Change Between the Two? Whichever medicine you use, results depend on what happens around the injection. Protein-rich meals, strength exercise, enough water, good sleep and regular check-ups help you keep muscle, reduce side effects and keep the weight off. That is the reason many people prefer tablets over injections. |
Lifestyle and Ayurvedic Care at Madhavbaug for Weight Loss
Managing weight is easier when your treatment plan considers your overall health, not just the number on the weighing scale. At Madhavbaug, doctors assess your weight, waist circumference, blood sugar, blood pressure and cholesterol before planning dietary changes, physical activity, sleep habits and personalised Ayurvedic care.
If you take prescription medicines, including weight-loss or diabetes injections, inform your doctor before starting any new treatment.
If you are struggling to manage your weight or blood sugar, visit your nearest Madhavbaug clinic for a health assessment and guidance suited to your needs. Learn more about our obesity care programme and diabetes care to understand how we approach weight and metabolic health together.
For appointments or general enquiries, reach out to your nearest Madhavbaug clinic.
Frequently Asked Questions
What is the difference between Mounjaro and Ozempic?
Mounjaro contains tirzepatide, which copies two gut hormones (GIP and GLP-1). Ozempic contains semaglutide, which copies one (GLP-1). Both are once-weekly injections, and they are made by different companies.
Is Mounjaro stronger than Ozempic?
In trials, tirzepatide produced more average weight loss than semaglutide, about 20 per cent against about 14 per cent over 72 weeks in adults with obesity. Doses are not directly comparable, and individual results vary.
Is Ozempic or Mounjaro better for weight loss?
On average, tirzepatide has shown greater weight loss in a head-to-head trial. The better choice for you depends on your health, tolerance, cost and access, and should be decided with your doctor.
What is tirzepatide in India?
Tirzepatide is the active medicine in Mounjaro, sold in India by Eli Lilly for type 2 diabetes and for weight management in adults who meet the approved criteria.
Are the side effects of Mounjaro and Ozempic the same?
They are very similar. Stomach and gut symptoms are the most common. Both carry warnings for pancreatitis, gallbladder problems and possible thyroid tumour risk seen in animals.
Can I switch from Ozempic to Mounjaro?
Only under your doctor’s advice. The doses are not equal, and the dose needs to be restarted or adjusted carefully.
Can I take Mounjaro and Ozempic together?
No. They act on the same pathway, and combining them raises the risk of side effects without a proven benefit.
References
Aronne, L.J., Horn, D.B., le Roux, C.W., et al. (2025) ‘Tirzepatide as compared with semaglutide for the treatment of obesity’, New England Journal of Medicine, 393(1), pp. 26-36.
Coskun, T., Sloop, K.W., Loghin, C., et al. (2018) ‘LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept’, Molecular Metabolism, 18, pp. 3-14.
Frias, J.P., Davies, M.J., Rosenstock, J., et al. (2021) ‘Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes’, New England Journal of Medicine, 385(6), pp. 503-515.
Lincoff, A.M., Brown-Frandsen, K., Colhoun, H.M., et al. (2023) ‘Semaglutide and cardiovascular outcomes in obesity without diabetes’, New England Journal of Medicine, 389(24), pp. 2221-2232.
Marso, S.P., Bain, S.C., Consoli, A., et al. (2016) ‘Semaglutide and cardiovascular outcomes in patients with type 2 diabetes’, New England Journal of Medicine, 375(19), pp. 1834-1844.
Locate a Centre
